Taiwan Liposome OA therapy hits mark in Phase II trial

Months after proposing a second listing on NASDAQ, Taiwan Liposome Co. Ltd. (TPEx:4152) said the lower of two doses of its lead candidate TLC599 met the primary endpoint in a Phase II trial to treat knee osteoarthritis pain. The therapy is a lipid-encapsulated formulation of dexamethasone.

Taiwan Liposome President George Yeh declined to say whether the study's higher dose met the endpoint, but told BioCentury the company will have a full analysis within a few weeks. Taiwan Liposome said it will discuss next steps with regulatory authorities and will present full data at a scientific conference...